Kamada Ltd. (KMDA)

NASDAQ: KMDA · IEX Real-Time Price · USD
4.77
+0.05 (1.04%)
Jun 2, 2023, 3:59 PM EDT - Market closed
1.04%
Market Cap 214.32M
Revenue (ttm) 131.96M
Net Income (ttm) -2.30M
Shares Out 44.84M
EPS (ttm) -0.05
PE Ratio n/a
Forward PE 10.33
Dividend n/a
Ex-Dividend Date n/a
Volume 30,801
Open 4.72
Previous Close 4.72
Day's Range 4.70 - 4.78
52-Week Range 3.72 - 5.72
Beta 0.24
Analysts Strong Buy
Price Target 11.00 (+130.66%)
Earnings Date May 24, 2023

About KMDA

Kamada Ltd. provides plasma-derived protein therapeutics. It operates in two segments, Proprietary Products and Distribution. The company offers KAMRAB/KEDRAB for prophylaxis of rabies disease; CYTOGAM for prophylaxis of cytomegalovirus disease in kidney, lung, liver, pancreas, heart, and heart/lung transplant; WINRHO SDF for immune thrombocytopenic purpura and suppression of rhesus isoimmunization; HEPAGAM B for prevention of hepatitis B recurrence liver transplants and post-exposure prophylaxis; VARIZIG for post exposure prophylaxis of varice... [Read more]

Sector Healthcare
Founded 1990
Employees 380
Stock Exchange NASDAQ
Ticker Symbol KMDA
Full Company Profile

Financial Performance

In 2022, Kamada's revenue was $129.34 million, an increase of 24.79% compared to the previous year's $103.64 million. Losses were -$2.32 million, 4.08% more than in 2021.

Financial Statements

Analyst Forecast

According to one analyst, the rating for KMDA stock is "Strong Buy" and the 12-month stock price forecast is $11.0.

Price Target
$11.0
(130.66% upside)
Analyst Consensus: Strong Buy
Stock Forecasts

News

Kamada Reports Strong First Quarter 2023 Financial Results; Reiterates Revenue and Profitability Guidance

REHOVOT, Israel and Hoboken, N.J., May 24, 2023 (GLOBE NEWSWIRE) -- Kamada Ltd. (NASDAQ: KMDA; TASE: KMDA.TA), a commercial stage global biopharmaceutical company, with a portfolio of marketed product...

1 week ago - GlobeNewsWire

Kamada Announces Chief Financial Officer Chaime Orlev to Remain in Role and Appointment of Nir Livneh as Vice President, General Counsel and Corporate Secretary

REHOVOT, Israel and HOBOKEN, N.J., May 24, 2023 (GLOBE NEWSWIRE) -- Kamada Ltd. (NASDAQ: KMDA; TASE: KMDA.TA) (“Kamada” or the “Company”), a commercial stage global biopharmaceutical company with a po...

1 week ago - GlobeNewsWire

Kamada Announces $60 Million Private Placement with FIMI Opportunity Funds

Funding to Support Kamada's Growth Plans and Execution of Strategic Business Development Opportunities Funding to Support Kamada's Growth Plans and Execution of Strategic Business Development Opportun...

1 week ago - GlobeNewsWire
}

Kamada to Announce First Quarter 2023 Financial Results and Host Conference Call on May 24, 2023

REHOVOT, Israel and HOBOKEN, N.J., May 17, 2023 (GLOBE NEWSWIRE) -- Kamada Ltd. (NASDAQ & TASE: KMDA), a commercial stage global biopharmaceutical company with a portfolio of marketed products indicat...

2 weeks ago - GlobeNewsWire

Kamada Announces Receipt of Marketing Authorization for Glassia® for Treatment of Alpha-1 Antitrypsin Deficiency in Switzerland

REHOVOT, Israel and HOBOKEN, N.J., May 16, 2023 (GLOBE NEWSWIRE) -- Kamada Ltd. (NASDAQ: KMDA; TASE: KMDA.TA), a commercial stage global biopharmaceutical company with a portfolio of marketed products...

2 weeks ago - GlobeNewsWire

Kamada Announces U.S. FDA Approval of its Application to Manufacture CYTOGAM® at the Company's Facility in Israel

REHOVOT, Israel and HOBOKEN, N.J., May 03, 2023 (GLOBE NEWSWIRE) -- Kamada Ltd. (NASDAQ: KMDA; TASE: KMDA.TA), a vertically integrated global biopharmaceutical company, focused on specialty plasma-der...

1 month ago - GlobeNewsWire

Kamada Issues 2023 CEO Letter to Shareholders

REHOVOT, Israel and HOBOKEN, N.J., March 15, 2023 (GLOBE NEWSWIRE) -- Kamada Ltd. (NASDAQ: KMDA; TASE: KMDA.TA), a commercial stage global biopharmaceutical company with a portfolio of marketed produc...

2 months ago - GlobeNewsWire

Kamada Reports Strong Fiscal Year and Fourth Quarter 2022 Financial Results, and Provides 2023 Guidance Representing Significant Profitability Growth

REHOVOT, Israel and Hoboken, N.J., March 15, 2023 (GLOBE NEWSWIRE) -- Kamada Ltd. (NASDAQ: KMDA; TASE: KMDA.TA), a commercial stage global biopharmaceutical company with a portfolio of marketed produc...

2 months ago - GlobeNewsWire
}

Kamada Announces Submission of Application to the U.S. FDA to Manufacture CYTOGAM® at the Company's Facility in Israel

REHOVOT, Israel and HOBOKEN, N.J. , Jan. 04, 2023 (GLOBE NEWSWIRE) -- Kamada Ltd. (NASDAQ: KMDA; TASE: KMDA.TA), a vertically integrated global biopharmaceutical company, focused on specialty plasma-d...

5 months ago - GlobeNewsWire

Kamada Announces Planned Transition of Chief Financial Officer

REHOVOT, Israel and HOBOKEN, N.J., Dec. 19, 2022 (GLOBE NEWSWIRE) -- Kamada Ltd. (NASDAQ: KMDA; TASE: KMDA.TA), a vertically integrated global biopharmaceutical company, focused on specialty plasma-de...

5 months ago - GlobeNewsWire

Kamada Reports Strong Third Quarter Financial Results Demonstrating Successful Strategic Transition and Reiterates 2022 Financial Guidance

REHOVOT, Israel and HOBOKEN, N.J., Nov. 22, 2022 (GLOBE NEWSWIRE) -- Kamada Ltd. (NASDAQ: KMDA; TASE: KMDA.TA), a vertically integrated global biopharmaceutical company, focused on specialty plasma-de...

6 months ago - GlobeNewsWire

Kamada Awarded $22 Million Extension of Canadian Supply Tender

REHOVOT, Israel and HOBOKEN, N.J., Oct. 19, 2022 (GLOBE NEWSWIRE) -- Kamada Ltd. (NASDAQ & TASE: KMDA), a vertically integrated global biopharmaceutical company, focused on specialty plasma-derived th...

8 months ago - GlobeNewsWire

Kamada Reports Second Quarter and First Half 2022 Financial Results; Significant Growth Driven by Multiple Catalysts Expected in Second Half of 2022; Reiterates 2022 Revenue and Profitability Guidance

REHOVOT, Israel, and HOBOKEN, N.J., Aug. 17, 2022 (GLOBE NEWSWIRE) -- Kamada Ltd. (NASDAQ: KMDA; TASE: KMDA.TA), a vertically integrated global biopharmaceutical company, focused on specialty plasma-d...

10 months ago - GlobeNewsWire
}

Kamada to Announce Second Quarter and First Half Ended June 30, 2022 Financial Results and Host Conference Call on August 17, 2022

REHOVOT, Israel and HOBOKEN, N.J., Aug. 10, 2022 (GLOBE NEWSWIRE) -- Kamada Ltd. (NASDAQ & TASE: KMDA), a vertically integrated global biopharmaceutical company, focused on specialty plasma-derived th...

10 months ago - GlobeNewsWire

Kamada Announces Resolution to the Labor Strike at the Company's Manufacturing Facility in Israel; A New, Eight-Year Collective Agreement Signed

REHOVOT, Israel, July 15, 2022 (GLOBE NEWSWIRE) -- Kamada Ltd. (Nasdaq: KMDA) (KMDA.TA), a vertically integrated global biopharmaceutical company, focused on specialty plasma-derived therapeutics, ann...

11 months ago - GlobeNewsWire

Kamada Announces $11.4 Million International VARIZIG® Procurement Agreement

REHOVOT, Israel and HOBOKEN, N.J., July 06, 2022 (GLOBE NEWSWIRE) -- Kamada Ltd. (NASDAQ & TASE: KMDA), a vertically integrated global biopharmaceutical company, focused on specialty plasma-derived th...

11 months ago - GlobeNewsWire

Kamada Strengthens Senior Leadership Team; Furthering Commitment as a Fully Integrated Global Leader in the Specialty Plasma-Derived Therapeutics Market

REHOVOT, Israel, and HOBOKEN, N.J., June 15, 2022 (GLOBE NEWSWIRE) -- Kamada Ltd. (NASDAQ & TASE: KMDA), a vertically integrated global biopharmaceutical company, focused on specialty plasma-derived t...

1 year ago - GlobeNewsWire

Kamada Reports First Quarter 2022 Financial Results; Reiterates Revenue and Profitability Guidance with Significant Growth Expected in 2022

REHOVOT, Israel, May 17, 2022 (GLOBE NEWSWIRE) -- Kamada Ltd. (NASDAQ: KMDA; TASE: KMDA.TA), a vertically integrated global biopharmaceutical company, focused on specialty plasma-derived therapeutics,...

1 year ago - GlobeNewsWire

Kamada to Announce First Quarter Ended March 31, 2022 Financial Results and Host Conference Call on May 17, 2022

REHOVOT, Israel, May 11, 2022 (GLOBE NEWSWIRE) -- Kamada Ltd. (NASDAQ & TASE: KMDA), a vertically integrated global biopharmaceutical company, focused on specialty plasma-derived therapeutics, today a...

1 year ago - GlobeNewsWire

Kamada Issues 2022 CEO Letter to Shareholders

REHOVOT, Israel, March 15, 2022 (GLOBE NEWSWIRE) -- Kamada Ltd. (NASDAQ: KMDA; TASE: KMDA.TA), a vertically integrated global biopharmaceutical company, focused on specialty plasma-derived therapeutic...

1 year ago - GlobeNewsWire

Kamada Reports Fiscal Year and Fourth Quarter 2021 Financial Results; Provides Revenue and Profitability Guidance with Significant Growth Expected in 2022

REHOVOT, Israel, March 15, 2022 (GLOBE NEWSWIRE) -- Kamada Ltd. (NASDAQ: KMDA; TASE: KMDA.TA), a vertically integrated global biopharmaceutical company, focused on specialty plasma-derived therapeutic...

1 year ago - GlobeNewsWire

Kamada Stock Jumps After Acquisition Of Four Plasma-Derived Products

Kamada Ltd (NASDAQ: KMDA) has acquired four FDA-approved plasma-derived hyperimmune commercial products from Saol Therapeutics. Kamada will pay Saol a $95 million upfront payment and an additional $50...

1 year ago - Benzinga

Kamada: Q3 Earnings Insights

Kamada (NASDAQ:KMDA) reported its Q3 earnings results on Monday, November 22, 2021 at 08:00 AM. Here's what investors need to know about the announcement.

1 year ago - Benzinga

Kamada Announces Strategic Transformational Transaction Positioning the Company as a Global Leader in the Plasma-Derived Hyperimmune Market Through the Acquisition of a Portfolio of Four FDA-Approved Commercial Products

REHOVOT, Israel, Nov. 22, 2021 (GLOBE NEWSWIRE) -- Kamada Ltd. (NASDAQ: KMDA; TASE: KMDA.TA), a plasma-derived biopharmaceutical company, today announced that it has acquired a portfolio of four U.S. ...

1 year ago - GlobeNewsWire

Kamada Reports Third Quarter and First Nine Months of 2021 Financial Results, and Strategic Transformational Acquisition of a Portfolio of Four FDA-Approved Plasma-Derived Hyperimmune Commercial Products

REHOVOT, Israel, Nov. 22, 2021 (GLOBE NEWSWIRE) -- Kamada Ltd. (NASDAQ: KMDA; TASE: KMDA.TA), a plasma-derived biopharmaceutical company, today announced financial results for the three and nine month...

1 year ago - GlobeNewsWire